Department of Obstetrics and Gynecology, Inonu University Faculty of Medicine, Malatya, Turkey.
Arch Gynecol Obstet. 2012 Sep;286(3):777-83. doi: 10.1007/s00404-012-2390-7. Epub 2012 May 31.
The current study investigated the potential therapeutic efficiency of atosiban, an oxytocin receptor antagonist, in an experimental endometriosis model.
Endometriosis was surgically induced in 35 female rats during estrus. Four weeks after this procedure, relaparotomy was performed. The viability and dimensions of the endometriosis foci were recorded. Rats were then randomly divided into three groups. In the first group (n = 8), a daily dose of 0.2 ml 0.9 % NaCl was injected intraperitoneally (i.p.) (control cases). In the second and third groups (n = 8 and n = 8), 0.5 mg/kg/day i.p. atosiban and 1 mg/day i.p. diltiazem were given, respectively. At the end of the treatment, laparotomy was performed, and the dimensions of the endometriosis foci were recorded. The endometrial implants were processed for histological and immunohistochemical studies. The volumes of endometriotic implants were measured, and immunohistochemical analyses were performed, and compared between the groups.
After the treatment with atosiban, volumes of endometriotic implants decreased significantly. Proliferating cell nuclear antigen expression levels were significantly reduced in the atosiban and diltiazem groups compared with the control group.
In a rat endometriosis model, atosiban, an agent used for the first time for the medical treatment of endometriosis, has shown significant therapeutic efficiency.
本研究旨在探讨催产素受体拮抗剂阿托西班在子宫内膜异位症实验模型中的潜在治疗效果。
在发情期对 35 只雌性大鼠进行手术诱导子宫内膜异位症。在该手术 4 周后进行再次剖腹术，记录子宫内膜异位症病灶的活力和大小。然后，将大鼠随机分为三组。第一组（n=8）每天腹膜内注射 0.2ml 0.9%生理盐水（对照组）。第二组和第三组（n=8 和 n=8）分别给予 0.5mg/kg/天腹膜内注射阿托西班和 1mg/天腹膜内注射地尔硫卓。治疗结束时进行剖腹术，记录子宫内膜异位症病灶的大小。对子宫内膜植入物进行组织学和免疫组织化学研究。测量子宫内膜异位症病灶的体积，并对各组之间的免疫组织化学分析进行比较。
阿托西班治疗后，子宫内膜异位症病灶的体积明显减小。与对照组相比，阿托西班和地尔硫卓组的增殖细胞核抗原表达水平明显降低。
在大鼠子宫内膜异位症模型中，阿托西班作为治疗子宫内膜异位症的第一种药物，显示出显著的治疗效果。
